303.06
+0.72%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Krystal Biotech
From its filings with the US Securities and Exchange Commission
Krystal Biotech is based in Pittsburgh, Pennsylvania. Its shares trade on Nasdaq under the ticker KRYS. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $389.1m and net income of $204.8m. At that date it held total assets of $1.33bn and shareholders' equity of $1.22bn.
We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 (“HSV-1”), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the transgene to treat the disease. Our vectors are amenable to formulation for non-invasive or minimally invasive routes of administration at a healthcare professional’s office or in the patient’s home by a healthcare professional, caregiver, or directly by the patient themselves. Our innovative technology platform is supported by two in-house, commercial scale Current Good Manufacturing Practice (“CGMP”) manufacturing facilities.
Our first commercial product, VYJUVEK®, is now approved in the United States, the European Union (“EU”), and Japan for the treatment of dystrophic epidermolysis bullosa (“DEB”). We launched VYJUVEK in the United States in 2023 and started launching VYJUVEK in Europe and Japan in 2025.
Quoted from its 10-K, filed 17 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Sept 2017
- Employees
- 295
- Website
- krystalbio.com ↗
- Head office
- 2100 WHARTON STREET, PITTSBURGH, PA, 15203
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Krish KrishnanChairman of the Board, President, Chief Executive Officer, since 2016$15.6m
- Ms. Suma KrishnanPresident - Research and Development, Founder, Director, since 2016$8.2m
- Ms. Kathryn RomanoChief Accounting Officer$3.1m
- Mr. Daniel JanneyLead Independent Director$702,694
- Mr. Julian GangolliIndependent Director$670,194
- Mr. Kirti GanorkarIndependent Director
- Dr. Adm. Christopher MasonIndependent Director$648,194
- Ms. Catherine MazzaccoIndependent Director$650,194
- Mr. Dino RossiIndependent Director$670,194
- Dr. Everett SutherlandIndependent Director$655,194
- Ms. Meg DodgeInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 65
- Environment
- 53
- Social
- 75
- Governance
- 67
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Krystal Biotech Inc possesses several unique strengths that contribute to its competitive advantage in the biotech industry. Firstly, the company has a strong research and development team comprising highly skilled scientists and experts. Their expertise allows Krystal Biotech to continuously innovate and develop cutting-edge gene therapy products.
- Another key strength of Krystal Biotech is its proprietary technology platforms. The company's advanced gene delivery system enables efficient and targeted delivery of genetic therapies, offering potential breakthrough treatments for various diseases. This technology provides a significant advantage over competitors.
Weaknesses
- Despite its strengths, Krystal Biotech Inc faces some weaknesses that could impact its performance. One notable weakness is the company's relatively small scale compared to larger biotech firms. Limited resources and infrastructure may hinder the company's ability to quickly scale up production or compete on the same level as industry giants.
- Additionally, as a relatively young company, Krystal Biotech may lack the extensive market experience and established partnerships that larger competitors possess. This could make it more challenging for the company to penetrate new markets or negotiate favorable business deals.
Opportunities
- Krystal Biotech Inc operates in an industry with vast opportunities for growth. The increasing demand for gene therapy products and personalized medicine presents a significant opportunity for the company to expand its market presence and generate substantial revenue.
- Furthermore, Krystal Biotech can explore strategic collaborations with academic institutions and other biotech companies to leverage shared resources, expertise, and enhance research capabilities. Such partnerships can lead to accelerated development of new therapies, paving the way for additional revenue streams and market collaborations.
Threats
- Despite the opportunities, Krystal Biotech also faces certain threats that could impact its competitive position. One such threat is the highly regulated nature of the biotech industry. Stringent regulatory processes and compliance requirements can result in delays or even failure in obtaining necessary approvals for product commercialization.
- Additionally, potential competition from established biotech companies and emerging startups poses a threat to Krystal Biotech's market share. The industry's rapid pace of innovation means that competitors may quickly develop similar gene therapies, potentially eroding the company's competitive advantage.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.